About Bienta

Bienta is a trademark for preclinical biology services of Enamine, the world’s largest supplier of drug-like molecules for drug discovery research. Bienta is operating as a Contract Research Organisation (CRO) providing biomolecular screening (HTS) services as well as comprehensive bioanalytical support of drug discovery projects, including in vitro ADMET (absorption, distribution, metabolism, excretion, toxicity) testing as well as pharmacokinetics (PK) and toxicity studies in animals.

Time- and Cost-Effective Screening

Rapid direct access to the vast Enamine’s off-the shelf compound collection (Screening Collection) and Enamine’s explored virtual chemical space for drug-like structures (REAL Database™),  in combination with the powerful in-house chemoinformatics and molecular modeling, enables an exceptionally efficient iterative screening, making it possible to step forward from in silico screening sets to the lead generation stage in weeks.

High Throughput Screening & ADME-Tox Services

HTS Lab at Bienta is a well-equipped screening facility with a broad range of robotic liquid handling and signal readout technology capabilities as well as the capacity to run both biochemical and cell-based assays in 384-well plate format. Bioanalytical Lab is established to provide all common in vitro ADMET tests as well as analytical support of pharmacokinetics and animal tox services.

Discover your molecules with us

News & Events

IPAB Contest Results Publication in Nature Sci.Rep.

Just out of print: an article with the results of IPAB* contest in Japan was published in Nature Scientific Reports. A compound library was originally provided by Enamine Ltd. and contained 2,382,017 of the stock compounds. In this work, BIENTA performed high-throughput screening of the compounds, based on inhibition activity and results. The screening was conducted in three steps consisting of...

ELRIG Drug Discovery 2017

Please attend Enamine/Bienta G5 booth at the ELRIG Drug Discovery 2017 Meeting! At the photo: Iaroslava Kos, Ph.D., Bienta Business Development Manager, is presenting our poster “Differential Scanning Fluorimetry Provides High Throughput Data on Novel SIRT1 Inhibitors”. The poster is available here. Enamine/Bienta Booth at the  ELRIG Drug Discovery 2017 Meeting: Tetiana Matvijuk, Michael Bossert and Iaroslava...

Bienta at MIPTEC 2017 in Basel

Researchers from Bienta/Enamine presented a poster during MIPTEC exhibition’2017 in Basel, Switzerland: “Reduced cardiotoxicity of spiro-tetrahydropyran bupivacaine analogues”. The goal of this study was to create active structural analogs of bupivacaine with reduced general and cardiotoxicity due to in silico modifications designed to affect their interaction with Nav1.5 channel, which is believed to be the main target of bupivacaine toxicity. Poster Basel...

Read More